BIOGEN INC. (BIIB) Share buybacks
- Total buybacks · last 12 months (USD): Value $0.00; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2024-12-31..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2024-12-31..
Share buybacks
Overview →Financial period ending 2024-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $0.00 | Trailing-year cash paid for share repurchases. Period ending 2024-12-31. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 0.00 USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2024-12-31 | $0.00 | (m) | (m) |
| 2023-12-31 | $0.00 | (m) | (m) |
| 2023-09-30 | $0.00 | (m) | (m) |
| 2023-06-30 | $250.00M | (m) | (m) |
| 2022-12-31 | $750.00M | (m) | (m) |
| 2022-09-30 | $750.00M | (m) | (m) |
| 2022-06-30 | $1.25B | (m) | (m) |
| 2022-03-31 | $1.20B | (m) | (m) |
| 2021-12-31 | $1.80B | (m) | (m) |
| 2021-09-30 | $2.20B | (m) | (m) |
| 2021-06-30 | $2.70B | (m) | (m) |
| 2021-03-31 | $5.06B | (m) | (m) |
| 2020-12-31 | $6.68B | (m) | (m) |
| 2020-09-30 | $8.37B | (m) | (m) |
| 2020-06-30 | $7.84B | (m) | (m) |
| 2020-03-31 | $7.43B | (m) | (m) |
| 2019-12-31 | $5.87B | (m) | (m) |
| 2019-09-30 | $5.13B | (m) | (m) |
| 2019-06-30 | $4.41B | (m) | (m) |
| 2019-03-31 | $4.76B | (m) | (m) |
| 2018-12-31 | $4.35B | (m) | (m) |
| 2018-09-30 | $3.00B | (m) | (m) |
| 2018-06-30 | $3.00B | (m) | (m) |
| 2018-03-31 | $1.03B | (m) | (m) |
| 2017-12-31 | $1.37B | (m) | (m) |
| 2017-09-30 | $2.02B | (m) | (m) |
| 2017-06-30 | $2.37B | (m) | (m) |
| 2017-03-31 | $1.58B | (m) | (m) |
| 2016-12-31 | $1.00B | (m) | (m) |
| 2016-09-30 | $2.35B | (m) | (m) |
| 2016-06-30 | $4.96B | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) |
| 2015-12-31 | $5.00B | (m) | (m) |
| 2015-09-30 | $3.52B | (m) | (m) |
| 2015-06-30 | $592.07M | (m) | (m) |
| 2014-12-31 | $886.78M | (m) | (m) |
| 2014-09-30 | $359.98M | (m) | (m) |
| 2014-06-30 | $696.19M | (m) | (m) |
| 2014-03-31 | $359.29M | (m) | (m) |
| 2013-12-31 | $400.31M | (m) | (m) |
| 2013-09-30 | $421.85M | (m) | (m) |
| 2013-06-30 | $115.79M | (m) | (m) |
| 2013-03-31 | $562.57M | (m) | (m) |
| 2012-12-31 | $984.72M | (m) | (m) |
| 2012-09-30 | $1.07B | (m) | (m) |
| 2012-06-30 | $1.02B | (m) | (m) |
| 2012-03-31 | $765.86M | (m) | (m) |
| 2011-12-31 | $497.98M | (m) | (m) |
| 2011-09-30 | $386.57M | (m) | (m) |
| 2011-06-30 | $854.82M | (m) | (m) |
| 2011-03-31 | $1.70B | (m) | (m) |
| 2010-12-31 | $2.08B | (m) | (m) |
| 2010-09-30 | $2.77B | (m) | (m) |
| 2010-06-30 | $2.30B | (m) | (m) |
| 2010-03-31 | $1.27B | (m) | (m) |
| 2009-12-31 | $751.17M | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) |
| 2008-12-31 | $738.94M | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) |
| 2007-12-31 | $2.99B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |